HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

500.836

-2.711-0.54%

Number of Gainers:7

Number of Losers:20

Number of Flat:6

PE:- -

High:512.805

Open:504.030

Low:499.921

Close:503.547

Volume:53.28M

Turnover:1.49B

Market Cap:316.90B

Float Cap:283.80B

Loading ...

Edding Genor Gets China Approval for Phase 2 GB268 Trial in Colorectal Cancer

MT Newswires Live

Everbright Securities Keeps "Buy" Rating on KEYMED BIO-B (02162) as Commercialization Ramps Up Rapidly

Everest Medicines Surges Over 12% in Morning Trading as Company Accelerates Global mRNA Strategy

How Can Domestic Innovative Drugs Truly Go Global for the Long Haul?

Hong Kong Stock Concept Tracking: Third-Quarter Earnings Season Begins! AI and Innovative Drugs in Focus, How Should Investors Position for the Q3 Earnings Rally? (With Concept Stocks)

Harbin Pharmaceutical Group President Lu Chuanyou Placed Under Investigation and Detention; Company Says Operations Remain Normal

China Securities Co., Ltd. Third Quarter 2026 Outlook on Pharma, Medical Devices and Services

Harbin Pharmaceutical's 64-Year-Old President Placed Under Detention; Earned Over 2.96 Million Yuan Last Year, Once Served as Chairman of Sanjing Pharmaceutical, Stock Once Rose 200% in 30 Trading Days

Breakeven On The Horizon For CARsgen Therapeutics Holdings Limited (HKG:2171)

Simply Wall St.

Is Akeso (SEHK:9926) Cheap As Its Phase III Colon Cancer Trial Expands Its Pipeline?

Simply Wall St.

mRNA Vaccine Hires Could Be A Game Changer For Everest Medicines (SEHK:1952)

Simply Wall St.

AI-Driven Drug Discovery Breaks Away as Policy, Deals and Clinical Data Converge

Fund Performance Rankings for the First Three Quarters: Semiconductors Dominate, Crude Oil Follows, Pharmaceuticals Rebound

InnoCare Turns Profitable and Lands Major Partnership, Yet Founding Families Keep Offloading Shares

Akeso Doses First Patient in Phase III Cadonilimab Perioperative Trial for MSI-H/dMMR Colon Cancer

Should Eli Lilly Drug Deal Require Action From InnoCare Pharma (SEHK:9969) Investors?

Simply Wall St.

BASECARE-B (02170) Spends HK$18,800 to Repurchase 15,000 Shares on October 9

Contec Medical Systems Secures Medical Device Registration Certificate for Color Doppler Ultrasound Diagnostic System

BASECARE-B (02170) Plans to Buy Back H-Shares for Up to RMB 5 Million

GF Securities Starts CStone Pharmaceuticals at Buy with HK$11.56 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigerhkgo.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":500.83646,"timestamp":1791785891015,"preClose":503.54697,"halted":0,"volume":53278981,"delay":0,"changeRate":-0.005383,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-2.71051,"latestTime":"10-12 14:18:12","open":504.02963,"high":512.8047,"low":499.92114,"amount":1487567918,"amplitude":0.025586,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791792600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791768600000,1791777600000],[1791781200000,1791792000000]],"pbRate":3.755372,"peRate":166.986761,"turnoverRate":0.002028,"increases":7,"decrements":20,"flats":5,"marketCap":316904717232,"floatMarketCap":283797390544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":512.8047,"amplitude":0.025586,"preClose":503.54697,"low":499.92114,"pbRate":"3.755372","latestPrice":500.83646,"volume":53278981,"delay":0,"open":504.02963,"prevYearClose":556.26263,"prevWeekClose":503.547,"prevMonthClose":532.388,"prevQuarterClose":532.388,"fiveDayClose":510.536,"twentyDayClose":483.155,"sixtyDayClose":473.886,"secType":"PLATE","market":"HK","turnoverRate":0.002028,"peRate":166.986761,"marketCap":316904717232,"floatMarketCap":283797390544,"timestamp":1791785891015,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":20,"flat":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674823949","title":"Edding Genor Gets China Approval for Phase 2 GB268 Trial in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674823949","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674823949?lang=en_us&edition=fundamental","pubTime":"2026-10-12 11:29","pubTimestamp":1791775788,"startTime":"0","endTime":"0","summary":"Edding Genor Group Holdings  received approval from China's National Medical Products Administration for a Phase 2 clinical trial of its investigational drug GB268 in advanced colorectal cancer, according to a Sunday Hong Kong bourse filing.The trial will evaluate GB268, a PD-1/CTLA-4/VEGF trispecific antibody, in combination with chemotherapy as a first-line treatment for patients with locally advanced or metastatic colorectal cancer that cannot be treated through curative surgery or local therapy.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06998","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158067159","title":"Everbright Securities Keeps \"Buy\" Rating on KEYMED BIO-B (02162) as Commercialization Ramps Up Rapidly","url":"https://stock-news.laohu8.com/highlight/detail?id=1158067159","media":"Stock News","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158067159?lang=en_us&edition=fundamental","pubTime":"2026-10-12 11:14","pubTimestamp":1791774857,"startTime":"0","endTime":"0","summary":"According to a research report from Everbright Securities Company Limited (601788), considering the rapid revenue growth of KEYMED BIO-B's (02162) core product Kangyueda in 26H1 and the substantial...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1587","BK0028","BK0012","BK0276","BK1583","BK1574","BK1161","601788","BK0183","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137700782","title":"Everest Medicines Surges Over 12% in Morning Trading as Company Accelerates Global mRNA Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1137700782","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137700782?lang=en_us&edition=fundamental","pubTime":"2026-10-12 09:51","pubTimestamp":1791769874,"startTime":"0","endTime":"0","summary":"Everest Medicines (01952) rose more than 12% in morning trading, with shares up 12.37% as of press time to HK$33.26, on turnover of HK$162 million.U.S. vaccine stocks rallied sharply last Friday,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01952","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165202895","title":"How Can Domestic Innovative Drugs Truly Go Global for the Long Haul?","url":"https://stock-news.laohu8.com/highlight/detail?id=1165202895","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165202895?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:31","pubTimestamp":1791761477,"startTime":"0","endTime":"0","summary":"Since the start of this year, the globalization of domestically developed innovative drugs has continued to advance, with multiple overseas licensing deals being finalized. Meanwhile, the industry is...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","IBBQ","BK1574","BK1161","MEDX","06978","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166516380","title":"Hong Kong Stock Concept Tracking: Third-Quarter Earnings Season Begins! AI and Innovative Drugs in Focus, How Should Investors Position for the Q3 Earnings Rally? (With Concept Stocks)","url":"https://stock-news.laohu8.com/highlight/detail?id=1166516380","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166516380?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:10","pubTimestamp":1791760243,"startTime":"0","endTime":"0","summary":"The third-quarter earnings disclosure window has officially opened, with listed companies beginning to release their results and many issuing advance earnings forecasts, some reporting net profit...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","QTOC","AGIX","KCAI","BK4585","MEDX","AIPO","06978","LNGR","VTHR","VXUS","ARTY","BK1161","CHAT","159992","BK4588","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197088385","title":"Harbin Pharmaceutical Group President Lu Chuanyou Placed Under Investigation and Detention; Company Says Operations Remain Normal","url":"https://stock-news.laohu8.com/highlight/detail?id=1197088385","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197088385?lang=en_us&edition=fundamental","pubTime":"2026-10-11 20:30","pubTimestamp":1791721851,"startTime":"0","endTime":"0","summary":"On October 11, Harbin Pharmaceutical Group Co., Ltd. issued an announcement disclosing that the company had recently received a \"Notice of Case Filing\" and a \"Notice of Detention\" from a supervisory...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181917803","title":"China Securities Co., Ltd. Third Quarter 2026 Outlook on Pharma, Medical Devices and Services","url":"https://stock-news.laohu8.com/highlight/detail?id=1181917803","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181917803?lang=en_us&edition=fundamental","pubTime":"2026-10-11 19:50","pubTimestamp":1791719441,"startTime":"0","endTime":"0","summary":"Pharma industry chain: 1) Prescription drugs: innovative access drives performance growth, while internationalization moves from business development to organizational overseas expansion and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDEV","BK0276","LGHT","159883","601066","09996","BK1574","BK1100","RSPH","AGNG","01477","LNGR","MEDX","HART","PTH","BK1583","GDOC","IEIH","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119173430","title":"Harbin Pharmaceutical's 64-Year-Old President Placed Under Detention; Earned Over 2.96 Million Yuan Last Year, Once Served as Chairman of Sanjing Pharmaceutical, Stock Once Rose 200% in 30 Trading Days","url":"https://stock-news.laohu8.com/highlight/detail?id=1119173430","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119173430?lang=en_us&edition=fundamental","pubTime":"2026-10-11 19:40","pubTimestamp":1791718830,"startTime":"0","endTime":"0","summary":"For stock trading, rely on Jinlin Analyst Research Reports — authoritative, professional, timely, and comprehensive, helping you uncover potential thematic opportunities! The 64-year-old president of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","BK1574","BK0239","01477","BK0012","BK1191","600664"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674450816","title":"Breakeven On The Horizon For CARsgen Therapeutics Holdings Limited (HKG:2171)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674450816","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674450816?lang=en_us&edition=fundamental","pubTime":"2026-10-11 10:05","pubTimestamp":1791684354,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited ( HKG:2171 ) is possibly approaching a major achievement in its business, so we...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/breakeven-on-the-horizon-for-carsgen-therapeutics-holdings-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/breakeven-on-the-horizon-for-carsgen-therapeutics-holdings-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1587","BK1161","BK4007","BK4139","LENZ","02171","BK1585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674164688","title":"Is Akeso (SEHK:9926) Cheap As Its Phase III Colon Cancer Trial Expands Its Pipeline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674164688","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674164688?lang=en_us&edition=fundamental","pubTime":"2026-10-11 08:30","pubTimestamp":1791678653,"startTime":"0","endTime":"0","summary":"Why this Phase III move matters for Akeso stock\nAkeso (SEHK:9926) has kicked off a Phase III trial of cadonilimab in resectable MSI-H/dMMR colon cancer, marking a new indication that could reshape expectations for its immuno-oncology portfolio.\nAkeso shares have picked up momentum in recent months, with a 16.56% 1 month share price return and 12.19% 3 month share price return at a last close of HK$109.1. However, the 1 year total shareholder return declined 14.77%, even as the 3 year total...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-akeso-sehk9926-cheap-as-its-phase-iii-colon-cancer-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-akeso-sehk9926-cheap-as-its-phase-iii-colon-cancer-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0417516738.SGD","LU0348766576.USD","LU0417516902.SGD","LU2778985437.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU2476274720.SGD","LU0348783233.USD","LU0540923850.HKD","LU0348767384.USD","BK1161","LU0348735423.USD","LU2488822045.USD","LU0348784397.USD","LU0348825331.USD","LU0348827113.USD","LU2399975544.HKD","09926","LU0634319403.HKD","BK1574","LU1720050803.USD","LU1794554557.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674813299","title":"mRNA Vaccine Hires Could Be A Game Changer For Everest Medicines (SEHK:1952)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674813299","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674813299?lang=en_us&edition=fundamental","pubTime":"2026-10-11 06:20","pubTimestamp":1791670846,"startTime":"0","endTime":"0","summary":"Everest Medicines has recently appointed Lakshmi Srinivasan, PhD, as Senior Vice President and Head of Translational Medicine, adding deep mRNA cancer vaccine and immunology expertise to its global R&D leadership bench.\nThis hire brings direct experience from Moderna and other mRNA players into Everest Medicines' AI plus mRNA platform, which could influence execution on upcoming oncology and autoimmune vaccine programs.\nThe focus now turns to how Everest Medicines' broader investment...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/mrna-vaccine-hires-could-be-a-game-changer-for-everest-medic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/mrna-vaccine-hires-could-be-a-game-changer-for-everest-medic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDCO","01952","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179067221","title":"AI-Driven Drug Discovery Breaks Away as Policy, Deals and Clinical Data Converge","url":"https://stock-news.laohu8.com/highlight/detail?id=1179067221","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179067221?lang=en_us&edition=fundamental","pubTime":"2026-10-10 22:26","pubTimestamp":1791642387,"startTime":"0","endTime":"0","summary":"Within the recent innovative drug sector, the AI drug discovery niche has quietly broken away from the broader market trend.Hong Kong-listed Genscript Biotech Corporation has seen steadily rising...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178015402","title":"Fund Performance Rankings for the First Three Quarters: Semiconductors Dominate, Crude Oil Follows, Pharmaceuticals Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1178015402","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178015402?lang=en_us&edition=fundamental","pubTime":"2026-10-10 16:41","pubTimestamp":1791621699,"startTime":"0","endTime":"0","summary":"During the first three quarters of 2026, the A-share market experienced a structural rally driven by the dual forces of domestic semiconductor substitution and the AI computing power wave, leading...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159582","CLmain","SMHX","USE","USO","DBO","SMHU","FWD","SOXX","FAAR","FTXN","OILU","BK4588","WTIU","SOXY","BZmain","SCO","XSD","DRLL","SOXS","BK1515","BK4585","DRIP","PXJ","BK1161","VGT","09939","IEO","NBDS","DIG","MCLmain","USL","VDE","MQQQ","BK4570","CHPY","CWC","GUSH","XES","UGA","USD","SOXQ","BK4535","DWT","IXC","OILT","TECY","PSI","USOI","DBC","UCO","OILK","CHPS","SOXL","SSG","DBE","PXE","SMH","OIH","DDG","XOP","BK1574","FTXL","TEKX","FLBR","159938","FBZ","ERX","DUG","BNO","QMmain","EIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155830129","title":"InnoCare Turns Profitable and Lands Major Partnership, Yet Founding Families Keep Offloading Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1155830129","media":"Deep News","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155830129?lang=en_us&edition=fundamental","pubTime":"2026-10-10 14:40","pubTimestamp":1791614444,"startTime":"0","endTime":"0","summary":"In the first half of 2026, InnoCare Pharma Limited (ASX: 09969) recorded operating revenue of 1.137 billion yuan, up 55.46% year on year, while net profit attributable to shareholders reached 246...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","BK0239","688428","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674895664","title":"Akeso Doses First Patient in Phase III Cadonilimab Perioperative Trial for MSI-H/dMMR Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674895664","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674895664?lang=en_us&edition=fundamental","pubTime":"2026-10-10 12:41","pubTimestamp":1791607307,"startTime":"0","endTime":"0","summary":"Akeso doses first patient in Phase III cadonilimab perioperative trial for MSI-H/dMMR colon cancerAkeso dosed the first patient in a Phase III perioperative trial of cadonilimab for resectable MSI-H o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261010:nNDL6m5sjr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","KURE","LU0417516902.SGD","LU0417516738.SGD","LU2778985437.USD","LU0348827113.USD","LU2476274308.USD","LU0561508036.HKD","LU0417516571.SGD","LU1794554557.SGD","BK1161","LU0348766576.USD","LU0348784397.USD","LU0348767384.USD","IE00B5MMRT66.SGD","09926","IE00B543WZ88.USD","LU0348825331.USD","LU2476274720.SGD","LU0348735423.USD","LU1961090484.USD","LU0348783233.USD","IE00BPRC5H50.USD","LU2399975544.HKD","LU1720050803.USD","LU2488822045.USD","LU0634319403.HKD","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674862996","title":"Should Eli Lilly Drug Deal Require Action From InnoCare Pharma (SEHK:9969) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674862996","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674862996?lang=en_us&edition=fundamental","pubTime":"2026-10-10 02:24","pubTimestamp":1791570264,"startTime":"0","endTime":"0","summary":"InnoCare Pharma announced a research collaboration and license agreement with Eli Lilly to pursue up to five drug targets addressing critical unmet medical needs.\nThe Eli Lilly partnership provides external validation for InnoCare Pharma's late stage pipeline, with potential implications for future commercialization and cash flow mix.\nThis article examines how InnoCare Pharma's investment narrative is shaped by the Eli Lilly collaboration around up to five targets.\n\nScan how the Eli Lilly...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/should-eli-lilly-drug-deal-require-action-from-innocare-phar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/should-eli-lilly-drug-deal-require-action-from-innocare-phar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","VOTE","BK1161","RGLO","JOYT","09969","BK4211","VGFPF","GXDW","PMDE","BK1574","FEBU","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164755503","title":"BASECARE-B (02170) Spends HK$18,800 to Repurchase 15,000 Shares on October 9","url":"https://stock-news.laohu8.com/highlight/detail?id=1164755503","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164755503?lang=en_us&edition=fundamental","pubTime":"2026-10-09 22:10","pubTimestamp":1791555021,"startTime":"0","endTime":"0","summary":"BASECARE-B (02170) issued an announcement that on October 9, 2026, it spent HK$18,800 to repurchase 15,000 shares.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1597","BK1574","02170","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119313877","title":"Contec Medical Systems Secures Medical Device Registration Certificate for Color Doppler Ultrasound Diagnostic System","url":"https://stock-news.laohu8.com/highlight/detail?id=1119313877","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119313877?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:00","pubTimestamp":1791543614,"startTime":"0","endTime":"0","summary":"Contec Medical Systems Co.,Ltd. (300869.SZ) has announced that the company recently obtained a Medical Device Registration Certificate of the People's Republic of China issued by the Hebei Provincial...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDEV","LNGR","PTH","09996","MEDX","GDOC","AGNG","HART","IEIH","300869","LGHT","BK1574","RSPH","159883","BK0251","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193035517","title":"BASECARE-B (02170) Plans to Buy Back H-Shares for Up to RMB 5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1193035517","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193035517?lang=en_us&edition=fundamental","pubTime":"2026-10-09 18:47","pubTimestamp":1791542856,"startTime":"0","endTime":"0","summary":"BASECARE-B (02170) has announced that its board of directors is pleased to declare its intention to exercise its powers under the buyback mandate, and the company will from time to time repurchase...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1222","BK1597","02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674559728","title":"GF Securities Starts CStone Pharmaceuticals at Buy with HK$11.56 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2674559728","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674559728?lang=en_us&edition=fundamental","pubTime":"2026-10-09 18:44","pubTimestamp":1791542660,"startTime":"0","endTime":"0","summary":"GF Securities Starts CStone Pharmaceuticals at Buy with HK$11.56 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":150,"code":"91000000","status":"200"}]}}